Interview with Alina Culcea, Managing Director, Actavis Romania
We understand that you already took over the reins at Actavis as interim GM in late 2009, before being officially appointed a few months later in 2010. What have been…
Address: Actavis Romania, Ion Mihalache Blvd. 11, sector 1, Bucharest 011 171, Romania
Tel: +40 21 351 45 67
Web: http://www.actavis.com.ro/ro/default.htm
Having joined Actavis Group in March 2006, the Romanian division strengthens the group’s oncology actavities. The Romanian branch embraces the Group’s center of excellence for the development, production and marketing of generic oncology medicines.
With a broad portfolio of oncology products, the company has a successful presence in a growing number of foreign markets. The latest market within the portfolio are in the United States and Japan, where since 2008, the company sells oncology products manufactured in the production unit in Bucharest – Sindan Pharma, a company previously acquired by Actavis Group in 2006.
Actavis offers its customers the broadest product portfolio and the most advanced production line of generic drugs. Currently, Actavis sells over 830 products (over 10,000 SKUs) in hospitals and pharmacies around the world, covering all relevant therapeutic areas. In 2008, the Company has launched over 660 products (235 molecules) and for 2009 it is expected that number to rise to 800 launches of new products.
We understand that you already took over the reins at Actavis as interim GM in late 2009, before being officially appointed a few months later in 2010. What have been…
Mirela Iordan country manager of Pfizer Romania reveals some of her milestones, including integrating new acquisitions and setting up the first financial centre in Europe for Pfizer. She shares her…
With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the…
According to a 2015 United Nations International Migration Report, since Romania joined the European Union in 2007, around 3.4 million Romanians have left the country in search of a better…
While the dismal regulatory environment in Romania has negatively affected the innovators with the uncertain and lengthy regulatory approval timelines as well as the dreaded ‘clawback tax’ doubling over the…
Stana Moisescu of Teva Pharmaceuticals Romania shares her insights on how to overcome unpredictability and inconsistency at the government level in Romania and why there needs to be a change…
Dan Minoiu, partner at Romanian law firm Mușat & Asociații, shares his insights into the main trends shaping the healthcare environment in Romania from a regulatory and legal perspective, the…
Despite the challenging characteristics of the Romanian market, with a large population of nearly 20 million people and significant unmet medical needs, the country will undoubtedly continue to be strategic…
Sévan Kaloustian shares his first impressions of the Romanian healthcare ecosystem and pharmaceutical market as newly appointed managing director of Janssen Pharmaceutical Companies of Johnson & Johnson Romania. Kaloustian outlines…
Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic…
Quite unfortunately, Romania has some of the highest infant mortality and maternal mortality rates in Europe, and even more worrying, the downward trend seems to be continuing, most notably with…
Appointed in August 2019 to head up Bayer Romania and Moldova’s Pharmaceuticals division, 15-year Bayer veteran Jorge Levinson may be new to the market but certainly not new to the…
Rostislav Hartman, general manager of the Czech Republic for Zimmer Biomet and who also looks after numerous countries in a dynamic region in Eastern Europe, introduces Zimmer Biomet’s historical presence…
See our Cookie Privacy Policy Here
